Sodium Glucose Cotransporter 2 Inhibition by Canagliflozin Attenuates Intrarenal Angiotensinogen Augmentation in Type 2 Diabetes Mellitus.

被引：0
|
作者：
Woods, T. Cooper [1 ]
Satou, Ryousule [1 ]
Miyata, Kayoko [1 ]
Katsurada, Akemi [1 ]
Dugas, Courtney M. [1 ]
Lightell, Daniel, Jr. [1 ]
Navar, L. Gabriel [1 ]
机构：
[1] Tulane Univ, Sch Med, 1430 Tulane Ave, New Orleans, LA 70112 USA
来源：
HYPERTENSION | 2017年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
AP464
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes
    Peters, Anne L.
    Henry, Robert R.
    Thakkar, Payal
    Tong, Cindy
    Alba, Maria
    DIABETES CARE, 2016, 39 (04) : 532 - 538
  • [22] Sodium glucose cotransporter 2 inhibitor, canagliflozin ameliorate liver function in Japanese patients with type 2 diabetes mellitus: Subgroup analyses of clinical trials
    Seko, Yuya
    Sumida, Yoshio
    Sasaki, Kazuyo
    Itoh, Yoshito
    Iijima, Hiroaki
    Hashimoto, Toshio
    Ishii, Shinichi
    Inagaki, Nobuya
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E797 - E798
  • [23] Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus
    Ahmadieh, Hala
    Ghazal, Nisrine
    Azar, Sami T.
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2017, 10 : 161 - 167
  • [24] Sodium glucose cotransporter 2 inhibition with empagliflozin reduces microalbuminuria in patients with type 2 diabetes
    Cherney, D.
    von Eynatten, M.
    Lund, S. S.
    Kaspers, S.
    Crowe, S.
    Woerle, H. J.
    Hach, T.
    DIABETOLOGIA, 2014, 57 : S333 - S333
  • [25] Use of Sodium-Glucose Cotransporter Type 2 Inhibitors in Older Adults with Type 2 Diabetes Mellitus
    Mikhail, Nasser
    SOUTHERN MEDICAL JOURNAL, 2015, 108 (02) : 91 - 96
  • [26] Dapagliflozin: A Novel Sodium-Glucose Cotransporter Type 2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
    Shah, Niren K.
    Deeb, Wasim E.
    Choksi, Rushab
    Epstein, Benjamin J.
    PHARMACOTHERAPY, 2012, 32 (01): : 80 - 94
  • [27] Inhibition kinetics and inhibitory mechanism of the sodium/glucose cotransporter (SGLT) 2 inhibitor canagliflozin
    Ohgaki, Ryuichi
    Wei, Ling
    Yamada, Kazunori
    Hara, Taiki
    Kuriyama, Chiaki
    Okuda, Suguru
    Ueta, Kiichiro
    Leclercq, Laurent
    Mamidi, Rao N. V. S.
    Shiotani, Masaharu
    Nagamori, Shushi
    Kanai, Yoshikatsu
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2017, 133 (03) : S231 - S231
  • [28] The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management
    Bo Xu
    Shaoqian Li
    Bo Kang
    Jiecan Zhou
    Cardiovascular Diabetology, 21
  • [29] Clinical effect of using a sodium-glucose cotransporter 2 inhibitor in type 2 diabetes mellitus
    Niu, Jiapeng
    Zhao, Lijuan
    Wang, Fei
    Wang, Jing
    Sun, Yanan
    Wang, Fang
    Gao, Yanyan
    Xian, Yuxin
    Li, Li
    Guo, Yunlei
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2020, 13 (12): : 9864 - 9870
  • [30] A New Hope in Type 2 Diabetes Mellitus Management: Sodium-Glucose Cotransporter 2 Inhibitors
    Chaurasia, Pallavi Prakash
    Dholariya, Sagar
    Kotadiya, Fenilkumar
    Bhavsar, Milav
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (09)
12345